NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes: the Hong Kong Diabetes Biobank
Authors' conclusion
NT-proBNP demonstrated a promising ability to serve as a prognostic marker for a variety of cardiorenal complications in type 2 diabetes. Considering NT-proBNP in clinical assessments could potentially help identify high-risk individuals who may benefit from more intensive therapies.
Study context
- Population
- People with T2D in the Hong Kong Diabetes Biobank, a multicentre prospective diabetes cohort
- Participants
- 1,993 samples
- Exposure
- Elevated NT-proBNP vs not elevated
- Outcome
- Incident cardiovascular and renal endpoints
Methodological detailsmulticentre, biobank
- Multicentre
- Biobank
Main finding
As reported in the abstract
Incident cardiorenal events, elevated vs non-elevated NT-proBNP
Each group vs non-elevated NT-proBNPEstimate (95% CI)P value
Elevated NT-proBNP
HR (AF) 4.64(2.44–8.85)
P < 0.001Elevated NT-proBNP
HR (CHD) 4.21(2.46–7.21)
P < 0.001Elevated NT-proBNP
HR (CVD) 3.32(2.20–5.01)
P < 0.001Elevated NT-proBNP
HR (CHF) 4.18(2.18–8.03)
P < 0.001Observational data: associations, not effects.
Further findings
Prevalence of elevated NT-proBNP · baseline
- Participants with elevated NT-proBNP
- 24.7%
Discrimination of elevated NT-proBNP (C index)
- CHD
- 0.83 (95% CI 0.76, 0.90)
- AF
- 0.88 (0.81, 0.94)
- Congestive heart failure (CHF)
- 0.89 (0.83, 0.95)
- 40% drop in eGFR
- 0.81 (0.77, 0.84)
- Kidney failure
- 0.88 (0.84, 0.92)
- Models with NT-proBNP had improved prediction vs established clinical risk models
- Sensitivity analyses (alternative cut-off, other CHD risk engines) yielded similar results
Original publication
NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes: the Hong Kong Diabetes Biobank. Diabetologia. Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →